恒瑞医药：自主研发创新药获批上市

Core Viewpoint - Heng Rui Medicine (600276) announced that its subsidiary, Shandong Shengdi Medicine, has received approval from the National Medical Products Administration for the drug registration certificate of its self-developed innovative drug, Regaglitin Metformin Tablets, marking a significant milestone in the company's product pipeline [1] Group 1: Product Development - The innovative drug is indicated for the treatment of adult patients with type 2 diabetes to improve blood glucose control when used in conjunction with diet and exercise [1] - Regaglitin Metformin Tablets are the first self-developed DPP-4 inhibitor combined with metformin fixed-dose formulation in China [1] - The total research and development investment for the Regaglitin Metformin Tablets project has reached approximately 76.6 million yuan [1]